CORTENDO  AB  Announces  Grant  of  Key  European  Patent   For  Treating Diabetes  and  Metabolic  Syndrome

Göteborg,  Sweden  –October  25,  2011.    Cortendo  AB  (CORT),  a   pioneer  in  the  development  of  innovative  therapies  in  the  field  of   diabetes  and  metabolic  syndrome  (MetS),  announced  today  that  the   European  Patent  Office  has  granted  key  intellectual  property  rights   related  to  its  core  technology  in  cortisol  regulation.  The  EPO  granted  a   core  patent  (EP1853266  B1)  entitled  ‘2S,  4R  Ketoconazole  for  Treating   Diabetes,  Metabolic  Syndrome  and  Other  Conditions”.    The  claims   broadly  relate  to  a  pharmaceutical  composition  for  use  in  the  treatment   of  various  conditions,  including  type  2  diabetes,  MetS,  Cushing’s   Syndrome,  lipid  disorders  and  conditions  that  can  be  treated  by   reducing  cortisol  synthesis.        

“Granting  of  this  key  patent  by  the  European  Patent  Office  validates   Cortendo’s  strategy  and  its  novel  treatment  approach  to  MetS  and   diabetes,”  said  H.  Joseph  Reiser  PhD,  CEO  of  Cortendo.    “This  new  patent   further  solidifies  Cortendo’s  leadership  position  in  cortisol  regulation,”   added  Dr.  Reiser.        Aside  from  the  granted  European  patent,  other  corresponding  national   patent  applications  are  currently  being  prosecuted  worldwide  with  two   additional  patents  issued.    Overall,  the  Cortendo  patent  estate  related  to   cortisol  regulation  includes  nearly  40  granted  patents  and  22  patents  in   multiple  patent  families  under  examination.

About Cortendo

Founded in 1996, Cortendo is a publicly traded, European based biopharmaceutical company that has pioneered cortisol inhibition as a treatment for Metabolic Syndrome (MES).  Lead drug candidate COR003, the 2S,4R-enantiomer of ketoconazole, is expected to enter Phase IIb clinical investigations for type 2 diabetes by the first quarter of 2012.  In parallel, Cortendo has plans to implement a broader pipeline expansion program existing of novel treatment approaches in diabetes and more near-term, revenue based opportunities.  Backed by a highly experienced leadership team, the Company’s expanded strategy will also include partnering discussions targeting the in-license of new programs in synergistic areas to provide future company growth and diversification.  For more information, please visit Cortendo’s website at www.cortendo.com.

Cortendo Forward-looking Statements

This press release contains forward-looking statements concerning Cortendo that involve a number of risks and uncertainties. All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding the Company’s future financial position, strategy, anticipated investments, costs and results, plans, projects to enhance efficiency, outcomes of products development, future capital expenditures, liquidity requirements and objectives of management for future operations, may be deemed to be forward‐looking statements. These forward‐looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements or industry results to be materially different from those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward‐looking statements. Given these risks and uncertainties, investors should not place any undue reliance on forward‐looking statements as a prediction of actual results. None of these forward‐looking statements constitutes a guarantee of the future occurrence of such facts and data or of actual results.  These statements are based on data, assumptions and estimates that the Company believes are reasonable. The forward‐looking statements contained in this document are made only as of the date hereof. The Company expressly disclaims any obligation or undertaking to release publicly any updates of any forward-looking statements contained in this press release to reflect any change in its actual results, assumptions, expectations or any change in events, factors, conditions or circumstances on which any forward‐looking statement contained in this press release is based.